Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35th Society for Immunotherapy of Cancer (SITC) virtual annual meeting. HPN601 is the first conditionally active T cell engager program from Harpoon. It targets the tumor antigen epithelial cell adhesion molecule (EpCAM) and is based on Harpoon’s proprietary ProTriTAC™ T cell engager prodrug platform designed to remain inert systemically until its activation in the tumor by tumor-associated proteases and to enable the safe targeting of broadly expressed tumor antigens.

The oral presentation today highlighted the following data:

  • The successful use of a humanized rodent tumor xenograft model to assess therapeutic index by simultaneously measuring efficacy and toxicity in the same tumor-bearing animal
  • A surrogate EpCAM ProTriTAC has a 10x improved therapeutic index compared to its corresponding constitutively active T cell engager control when measuring efficacy and toxicity in the same animal
  • Improved tolerability of HPN601 in non-human primates and more potent anti-tumor activity in a rodent tumor model over the corresponding constitutively active T cell engager control
  • Potent anti-tumor activity across multiple EpCAM-expressing tumor models, demonstrating the ability of HPN601 to be activated in multiple tumor types

“ProTriTAC represents a new and improved approach to engineer conditionally active T cell engager prodrugs that are designed to provide enhanced tumor specificity and enable an improved safety profile,” said Holger Wesche, Ph.D., chief scientific officer of Harpoon Therapeutics. “This enables T cell engagers to target tumor antigens that may otherwise be intractable due to expression on normal tissues. The data presented today for HPN601 support this therapeutic approach.”

Preclinical Results Presented for HPN601

The oral presentation at SITC, titled “HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors,” included the results of several preclinical investigations that support further development of this agent for the potential treatment of EpCAM-expressing solid tumors.

EpCAM is a tumor antigen that is broadly and uniformly expressed in many solid tumors; however, expression on some normal tissues has hindered its potential as a therapeutic target due to on-target, off-tumor toxicity as observed in clinical studies from past EpCAM targeted T cell engagers. Local administration of an EpCAM T cell engager was able to minimize normal tissue liability, but is not practical for the treatment of metastatic disease. The goal of developing HPN601, a conditionally active drug candidate, is to target all metastatic tumors by systemic administration and have an acceptable safety profile in line with local administration.

To assess therapeutic index, a humanized rodent tumor xenograft model was used to simultaneously measure efficacy and toxicity. A surrogate molecule of HPN601 was safely administered at a dose 10x higher than the minimal efficacious dose required for durable tumor regression. Higher doses produced clinically relevant toxicity including elevated liver transaminases and bilirubin, body weight loss, and evidence of tissue damage by histopathology. In contrast, a constitutively active EpCAM-targeting T cell engager could only be dosed safely up to its minimum efficacious dose, suggesting that the EpCAM ProTriTAC has a 10x improved therapeutic index.

The improved safely profile of HPN601 was also supported by a toxicokinetic study in non-human primates. HPN601 was better tolerated in non-human primates, with significantly attenuated cytokine production, than its constitutively active T cell engager control. Despite its better safety profile, HPN601 was also more efficacious than its constitutively active T cell engager control in a rodent tumor xenograft model. Taken together, the data indicates that HPN601, as a conditionally active T cell engager, has an expanded therapeutic index compared to a constitutively active T cell engager.

Given the breadth of EpCAM-expressing tumors, HPN601 was also assessed for its ability to be processed in different tumor types. HPN601 was tested in four different tumor xenograft models. Tumor regression was found in all four tumor models, with very good potency in three of the four models tested. This observation shows that HPN601, as a prodrug requiring proteolytic activation in the tumor, can be processed and activated in multiple tumor types.

Based on these encouraging preclinical data, as well as other preclinical and manufacturability assessments, HPN601 has been nominated as a clinical candidate and IND-enabling studies are now underway.

A copy of the presentation will be available on the company’s website at https://ir.harpoontx.com/events-and-presentations shortly after the event.

About ProTriTAC

Harpoon designed the ProTriTAC™ platform to expand the universe of addressable targets and indications for T cell engagers. IND enabling studies are underway for the first ProTriTAC™ clinical candidate, HPN601. ProTriTAC™ applies a prodrug concept to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Upon entering a tumor, tumor-associated proteases cleave off the blocking domain of the ProTriTAC™, thereby enabling the engagement of T cells to subsequently kill tumor cells. This activation process also diminishes the half-life of the resulting T cell engager. If active molecules leave the tumor tissue, they are rapidly eliminated from the body, further limiting the potential side effects in normal tissues.

About
Harpoon
Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1/2 trial in the fourth quarter of 2020. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, the timing of development milestones for product candidates, and the anticipated potential impacts to Harpoon Therapeutics’ business from the ongoing COVID-19 pandemic. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts
:

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
[email protected]

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
[email protected]

ABM Projected to Save GSA Southeast Sunbelt Region 4 an Estimated $34.3 Million

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility solutions, has initiated an additional Energy Savings Performance Contract (ESPC) for the U.S. General Services Administration (GSA). Over the 20-year period, ABM’s energy performance contract is projected to save an estimated $34.3 million generated by a projected average energy reduction of 37% for nine federal facilities in Alabama, Mississippi, and North Carolina. The project includes ventilation system upgrades to improve indoor air quality (IAQ) in all nine facilities.

“Indoor air quality is a concern for every employer and employee today, public and private,” said Mark Hawkinson, President of ABM Technical Solutions. “I’m happy we can create the savings they need to address these capital improvements to make sure these ventilation upgrades happen.”

As of this project, ABM has provided custom energy solutions to GSA totaling more than $100 million of capital invested. ABM has previously implemented a multiple-phase ESPC for GSA in Los Angeles, California, with the most recent phase described here.

ABM’s Energy Performance Contracting Program enables federal entities and others, such as schools and local governments, to invest in critical facility needs like air quality, infrastructure, and sustainability goals. The program is designed to drive costs out of a facility’s operating budget, redirecting savings to fund mission critical facility needs. This video outlines how ABM provides custom technical and financial solutions for government facilities without upfront costs or tax increases.

The project will restore a solar photovoltaic system de-energized due to unrepaired solar panel damage, saving much of the existing equipment. A new design will introduce redundancy to avoid shutdowns, including a monitoring system to help prevent and diagnose issues before they arise. HVAC renovations will significantly improve IAQ with better control of outdoor air, including more efficient use of fan energy and increased delivery of fresh air. Highlights of the project also include:

  • Optimizing chillers and boilers to improve energy efficiency
  • Retrofitting lighting with energy-saving LED lighting
  • Capital improvements to resolve issues impacting air quality and energy savings
  • Installing water conservation upgrades
  • Replacing high-efficiency transformers in electrical power distribution systems

The project includes upgrades to historic courthouses and provides new and upgraded Building Automation System (BAS) infrastructure and platforms to five of the nine locations, providing GSA centralized, real-time monitoring, analytics, and performance data. The BAS upgrades include advanced controls that enable significant reductions in the energy use of connected HVAC systems. The nine facilities are:

  • Dan M. Russell Jr. Courthouse, Gulfport, MS
  • Frank M. Johnson Jr. Federal Building & U.S. Courthouse, Montgomery, AL
  • Hiram H. Ward Federal Building & U.S. Courthouse, Winston-Salem, NC
  • L.R. Preyer Federal Building-Post-Office-Courthouse, Greensboro, NC
  • Terry Sanford Federal Building & U.S. Courthouse, Raleigh, NC
  • Thad Cochran U.S. Courthouse, Jackson, MS
  • U.S. Courthouse, Oxford, MS
  • Veach-Baley Federal Complex, Asheville, NC
  • William M. Colmer Federal Building & U.S. Courthouse, Hattiesburg, MS

For more information on ABM’s Energy Savings Performance Contracts and other offerings, visit www.abm.com.  

CONNECT WITH ABM

ABOUT ABM


ABM (NYSE: ABM)
is a leading provider of facility solutions with revenues of approximately $6.5 billion and more than 140,000 employees in 350+ offices throughout the United States and various international locations. ABM’s comprehensive capabilities include janitorial, electrical & lighting, energy solutions, facilities engineering, HVAC & mechanical, landscape & turf, mission critical solutions and parking, provided through stand-alone or integrated solutions. ABM provides custom facility solutions in urban, suburban and rural areas to properties of all sizes – from schools and commercial buildings to hospitals, data centers, manufacturing plants and airports. ABM Industries Incorporated, which operates through its subsidiaries, was founded in 1909. For more information, visit www.abm.com.

CONTACT

Media:

Kristy Miller
(678) 268-4242
[email protected]

Investor Relations
&
Treasury:

Susie A. Kim
(212) 297-9721
[email protected]

CooperCompanies Elects Teresa S. Madden to Board of Directors

SAN RAMON, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO) announced today that its Board of Directors elected Teresa S. Madden to the Board as an independent director, effective December 1, 2020.

“We are delighted to have Teresa join our Board of Directors,” said Al White, President and CEO. “Teresa brings a unique perspective that combines operational excellence and financial acumen, with long-term experience in an industry that was continually being pushed to evolve and change. We look forward to Teresa’s advice and support as Cooper continues growing its business.”

Ms. Madden is an independent director of Enbridge, Inc. (NYSE: ENB) where she serves on the governance committee and as chair of the audit, finance and risk committee. She previously served as a director of Peabody Energy Corporation (NYSE: BTU) from 2017 to 2020 where she served on the health, safety, security & environmental committee and as chair of the audit committee.

Ms. Madden served as Executive Vice President and Chief Financial Officer of Xcel Energy, Inc. (NASDAQ: XEL), an electric and natural gas utility, from 2011 until her retirement in 2016. She joined Xcel in 2003 as Vice President, Finance, Customer & Field Operations and was named Vice President and Controller in 2004. Previously, Ms. Madden served as Controller for Rogue Wave Software, Inc. from 2000 to 2003 and as Controller for New Century Energies and Public Service Company of Colorado, predecessor companies of Xcel Energy. She holds a Bachelor of Science degree in accounting from Colorado State University and Master of Business Administration degree from Regis University.

About CooperCompanies

CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
[email protected]

MONMOUTH REAL ESTATE TO PARTICIPATE IN NAREIT’S REITWORLD: 2020 VIRTUAL ANNUAL CONFERENCE

Holmdel, NJ, Nov. 12, 2020 (GLOBE NEWSWIRE) — Monmouth Real Estate Investment Corporation (NYSE:MNR) today announced that Michael P. Landy, President and Chief Executive Officer, Kevin Miller, Chief Financial Officer, and Becky Coleridge, Vice President of Investor Relations, are scheduled to participate in Nareit’s REITworld: 2020 Virtual Annual Conference.

Monmouth is scheduled to present on Tuesday, November 17, 2020, at 9:30 a.m. Eastern Time.

In order to view the presentation live or on-demand, you must register on the REITworld website.

Monmouth Real Estate Investment Corporation, founded in 1968, is one of the oldest public equity REITs in the world. The Company specializes in single tenant, net-leased industrial properties, subject to long-term leases, primarily to investment-grade tenants. Monmouth Real Estate is a fully integrated and self-managed real estate company, whose property portfolio consists of 119 properties containing a total of approximately 23.4 million rentable square feet, geographically diversified across 31 states. Our occupancy rate as of this date is 99.4%.

Contact: Becky Coleridge

732-577-9996

EMAIL: [email protected]
www.mreic.reit

# # # # #

5:01 Acquisition Corp. Announces Partial Exercise and Closing of Over-Allotment Option in Initial Public Offering

SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) — 5:01 Acquisition Corp. (the “Company”) (NASDAQ: FVAM) announced today that the underwriter of its previously announced initial public offering of Class A common stock, par value $0.0001 per share, partially exercised its over-allotment option resulting in the issuance of an additional 256,273 shares at a price to the public of $10.00 per share for gross proceeds of approximately $2.6 million.

The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

The Company’s shares of Class A common stock began trading on The Nasdaq Capital Market under the ticker symbol “FVAM” on October 14, 2020.

BofA Securities acted as sole book-running manager for the Company’s initial public offering. The Company granted the underwriter the option to purchase the shares described herein in connection with the Company’s initial public offering of 8,000,000 shares of its Class A common stock at a public offering price of $10.00 per share, which closed on October 16, 2020.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at [email protected].

A registration statement relating to this offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 13, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and any potential business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement for the Company’s offering filed with the SEC and the preliminary prospectus included therein. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact
5:01 Acquisition Corp.
Jason Ruth, Chief Business Officer
[email protected]
415-993-8570

Dolby Laboratories Reports Fourth Quarter and Fiscal 2020 Financial Results

SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the fourth quarter and fiscal year that ended September 25, 2020. For the fourth quarter, Dolby reported total revenue of $271.2 million, compared to $298.8 million for the fourth quarter of fiscal 2019. For fiscal 2020, Dolby reported total revenue of $1.16 billion, compared to $1.24 billion for fiscal 2019.

“Dolby experiences are expanding to a broader range of content,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “With the launch of iPhone 12, consumers are now able to create in Dolby Vision and we are also beginning to address content experiences and interactions within new use cases and industries as we enable developers through Dolby.io.”

Fourth quarter GAAP net income was $26.8 million, or $0.26 per diluted share, compared to GAAP net income of $43.9 million, or $0.43 per diluted share for the fourth quarter of fiscal 2019. On a non-GAAP basis, fourth quarter net income was $45.8 million, or $0.45 per diluted share, compared to $67.6 million, or $0.66 per diluted share for the fourth quarter of fiscal 2019. Fourth quarter cash flows from operations was $112.7 million, compared to $130.5 million for the fourth quarter of fiscal 2019. A complete listing of Dolby’s non-GAAP measures are described and reconciled to the corresponding GAAP measures at the end of this release. 

Fiscal 2020 GAAP net income was $231.4 million, or $2.25 per diluted share, compared to $255.2 million, or $2.44 per diluted share for fiscal 2019. On a non-GAAP basis, fiscal 2020 net income was $305.2 million, or $2.97 per diluted share, compared to $334.6 million, or $3.20 per diluted share, for fiscal 2019. Fiscal 2020 cash flows from operations was $343.8 million, compared to $327.7 million for fiscal 2019.

COVID-19

Dolby continues to monitor the COVID-19 pandemic and its impact on our company. Our priorities continue to be the safety and well-being of our employees and supporting our communities. Since the initial outbreak of COVID-19, our revenues have been, and we expect will continue to be, impacted across various markets within licensing and products and services. The implications of COVID-19 on our future results of operations remain uncertain.

We expect continued significant uncertainty in global financial markets. Dolby’s financial results for the fourth quarter of fiscal 2020 rely on estimates of royalty-based revenue that take into consideration the macroeconomic effect of global events, including the COVID-19 pandemic, which may impact supply chain activities and demand for shipments. For more information, see the section captioned “Critical Accounting Policies and Estimates” in our most recently filed Quarterly Report on Form 10-Q.

Dividend

Today, Dolby announced a cash dividend of $0.22 per share of Class A and Class B common stock, payable on December 4, 2020, to stockholders of record as of the close of business on November 24, 2020.

Financial Outlook – First and Second Quarters Fiscal 2021

Unit volume shipments, aggregated across various end markets and devices, continue to be impacted and difficult to predict because of economic uncertainty due to COVID-19, and it remains unclear when such unit volumes could return to pre-pandemic levels. The global cinema market has been adversely impacted by COVID-19 because of site closures or reduced utilization, and we anticipate that cinema sites could continue to be negatively affected through the first half of fiscal 2021 or longer.

Our actual results could differ materially from the estimates we are providing due in part to the challenging economic environment and highly uncertain effects of COVID-19. The estimates we are providing for future periods reflect certain assumptions about the potential impact of COVID-19, based upon a consideration of external and internal data and information. For more information, see “Forward-Looking Statements” in this press release for a description of certain risks that we face, and the section captioned “Risk Factors” in our most recently filed Quarterly Report on Form 10-Q.

First Quarter Fiscal 2021

Dolby is providing the following estimates for its first quarter of fiscal 2021:

  • Total revenue is estimated to range from $330 million to $360 million
  • Gross margin percentages are anticipated to range from 90% to 91% on a GAAP basis and from 91% to 92% on a non-GAAP basis
  • Operating expenses are anticipated to range from $207 million to $219 million on a GAAP basis and from $175 million to $185 million on a non-GAAP basis
  • Effective tax rate is anticipated to range from 20% to 21% on both a GAAP and non-GAAP basis
  • Diluted earnings per share is anticipated to range from $0.70 to $0.85 on a GAAP basis and from $0.97 to $1.12 on a non-GAAP basis

Second Quarter Fiscal 2021

Dolby is also providing the following estimate for its second quarter of fiscal 2021:

  • Total revenue is estimated to range from $270 million to $300 million

Conference Call Information

Members of Dolby management will lead a conference call open to all interested parties to discuss fourth quarter and fiscal 2020 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Thursday, November 12, 2020. Access to the teleconference will be available over the Internet from http://investor.dolby.com/event-calendar or by dialing 1-800-289-0438. International callers can access the conference call at 1-323-794-2423.

A replay of the call will be available from 5:00 p.m. PT on Thursday, November 12, 2020, until 8:59 p.m. PT on Thursday, November 19, 2020, by dialing 1-844-512-2921 (international callers can access the replay by dialing 1-412-317-6671) and entering the confirmation code 5368845. An archived version of the teleconference will also be available on the Dolby website, http://investor.dolby.com.

Non-GAAP Financial Information

To supplement Dolby’s financial statements presented on a GAAP basis, Dolby provides certain non-GAAP financial measures to provide investors with an additional tool to evaluate Dolby’s operating results in a manner that focuses on what Dolby’s management believes to be its ongoing business operations. Specifically, we exclude the following as adjustments from one or more of our non-GAAP financial measures:

Stock-based compensation expense: Stock-based compensation, unlike cash-based compensation, utilizes subjective assumptions in the methodologies used to value the various stock-based award types that we grant. These assumptions may differ from those used by other companies. To facilitate more meaningful comparisons between our underlying operating results and those of other companies, we exclude stock-based compensation expense.

Amortization of acquisition-related intangibles: We amortize intangible assets acquired in connection with acquisitions. These intangible assets consist of patents and technology, customer relationships, and other intangibles. We record amortization charges relating to these intangible assets in our GAAP financial statements, and we view these charges as items arising from pre-acquisition activities that are determined by the timing and valuation of our acquisitions. As these amortization charges do not directly correlate to our operations during any particular period, and often remain unchanged between reporting periods, we exclude these charges to facilitate an evaluation of our current operating results and comparisons to our past operating performance.

Restructuring charges: Restructuring charges are costs associated with restructuring plans and primarily relate to costs associated with exit or disposal activities, employee severance benefits, and asset impairments. We exclude restructuring costs, including any adjustments to charges recorded in prior periods, as we believe that these costs are not representative of our normal operating activities and therefore, excluding these amounts enables a more effective comparison to our past operating performance.

Income tax adjustments: We believe that excluding the income tax effect of the aforementioned non-GAAP adjustments provides a more accurate view of our underlying operating results to management and investors.

Impact from Tax Reform: The enactment of the U.S. Tax Cuts and Jobs Act (Tax Reform), and any related amendments or revisions, requires certain discrete and infrequent charges that are not representative of current operating results and therefore, excluding these amounts enables a more effective comparison to our past operating performance.

Using the aforementioned adjustments, Dolby provides various non-GAAP financial measures including, but not limited to: non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating margin, and non-GAAP effective tax rate. Dolby’s management believes it is useful for itself and investors to review both GAAP and non-GAAP measures to assess the performance of Dolby’s business. Dolby’s management does not itself, nor does it suggest that investors should, consider non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Whenever Dolby uses non-GAAP financial measures, it provides a reconciliation of the non-GAAP financial measures to the most closely applicable GAAP financial measures. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as detailed above. Investors are also encouraged to review Dolby’s GAAP financial statements as reported in its US Securities and Exchange Commission (SEC) filings. A reconciliation between GAAP and non-GAAP financial measures is provided at the end of this press release and on the Dolby investor relations website, http://investor.dolby.com.

Forward-Looking Statements

Certain statements in this press release, including, but not limited to, statements relating to Dolby’s expected financial results for the first and second quarters of fiscal 2021, our ability to advance our long-term objectives, and future dividend payments are “forward-looking statements” that are subject to risks and uncertainties. These forward-looking statements are based on management’s current expectations, and as a result of certain risks and uncertainties, actual results may differ materially from those provided. The following important factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the potential impacts of the COVID-19 pandemic on Dolby’s business operations, financial results, and financial position (including the impact to Dolby partners and disruption of the supply chain and delays in shipments of consumer products; consumer demand for products that incorporate Dolby technologies; delays in the development and release of new products or services that contain Dolby technologies; delays in royalty reporting or delinquent payment by partners or licensees; the impact to the overall cinema market, including closures or limitations of cinema capacity and resulting adverse impact to Dolby’s revenue recognized on box-office sales and demand for cinema products and services; temporary Dolby office closures and other actions to protect Dolby’s workforce; and macroeconomic conditions that affect discretionary spending and access to products that contain Dolby technologies); risks associated with trends in the markets in which Dolby operates, including the Broadcast, Mobile, Consumer Electronics, PC, Cinema, and Other Markets; the loss of, or reduction in sales by, a key customer or licensee; pricing pressures; risks that the continued shift in content distribution from optical disc-based and other traditional media to online and streaming media content could result in fewer devices with Dolby technologies or less revenue from such devices; risks relating to conducting business internationally, including trade restrictions and changes in diplomatic or trade relationships; risks relating to the expiration of patents; the timing of Dolby’s receipt of royalty reports and payments from its licensees, including recoveries; changes in tax regulations; timing of revenue recognition under licensing agreements and other contractual arrangements; Dolby’s ability to develop, maintain, and strengthen relationships with industry participants; Dolby’s ability to develop and deliver innovative technologies in response to new and growing markets; competitive risks; risks associated with conducting business in China and other countries that have historically limited recognition and enforcement of intellectual property and contractual rights; risks associated with the health of the motion picture industry generally; Dolby’s ability to increase its revenue streams and to expand its business generally, and to continue to expand its business beyond audio technologies to other technologies; risks associated with acquiring and successfully integrating businesses or technologies; and other risks detailed in Dolby’s SEC filings and reports, including the risks identified under the section captioned “Risk Factors” in our most recent quarterly report on Form 10-Q. Dolby disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

About Dolby Laboratories

Dolby Laboratories (NYSE: DLB) is based in San Francisco with offices in over 20 countries around the globe. Dolby transforms the science of sight and sound into spectacular experiences. Through innovative research and engineering, we create breakthrough experiences for billions of people worldwide through a collaborative ecosystem spanning artists, businesses, and consumers. The experiences people have – with Dolby Cinema, Dolby Vision, Dolby Atmos, Dolby Audio, and Dolby Voice – revolutionize entertainment and communications at the cinema, on the go, in the home, and at work. 

Dolby, Dolby Cinema, Dolby Vision, Dolby Atmos, Dolby Audio, Dolby Voice, and the double-D symbol are among the registered and unregistered trademarks of Dolby Laboratories, Inc. in the United States and/or other countries. Other trademarks remain the property of their respective owners. DLB-F







DOLBY LABORATORIES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts; unaudited)

  Fiscal Quarter Ended   Fiscal Year-To-Date Ended
  September 25,

2020
September 27,

2019
  September 25,

2020
September 27,

2019
Revenue:          
Licensing $ 256,904     $ 264,796       $ 1,078,577     $ 1,107,280    
Products and services 14,287     34,031       83,215     134,340    
Total revenue 271,191     298,827       1,161,792     1,241,620    
           
Cost of revenue:          
Cost of licensing 12,665     16,770       50,822     57,531    
Cost of products and services 29,800     29,190       95,676     103,323    
Total cost of revenue 42,465     45,960       146,498     160,854    
           
Gross margin 228,726     252,867       1,015,294     1,080,766    
           
Operating expenses:          
Research and development 61,726     60,191       239,045     237,871    
Sales and marketing 81,396     82,149       335,933     343,835    
General and administrative 55,581     53,013       219,753     205,425    
Restructuring charges/(credits) (45 )   6,294       1,821     36,558    
Total operating expenses 198,658     201,647       796,552     823,689    
           
Operating income 30,068     51,220       218,742     257,077    
           
Other income/expense:          
Interest income 494     5,689       12,725     24,919    
Interest expense (55 )   (64 )     (186 )   (170 )  
Other income/(expense), net 3,985     (594 )     8,434     481    
Total other income 4,424     5,031       20,973     25,230    
           
Income before income taxes 34,492     56,251       239,715     282,307    
Provision for income taxes (7,516 )   (12,316 )     (8,096 )   (26,802 )  
Net income including controlling interest 26,976     43,935       231,619     255,505    
Less: net (income) attributable to controlling interest (147 )   (17 )     (256 )   (354 )  
Net income attributable to Dolby Laboratories, Inc. $ 26,829     $ 43,918       $ 231,363     $ 255,151    
           
Net income per share:          
Basic $ 0.27     $ 0.44       $ 2.30     $ 2.51    
Diluted $ 0.26     $ 0.43       $ 2.25     $ 2.44    
Weighted-average shares outstanding:          
Basic 100,473     100,481       100,564     101,629    
Diluted 102,722     102,945       102,944     104,572    







DOLBY LABORATORIES, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands; unaudited)

  September 25,

2020
September 27,

2019
ASSETS    
Current assets:    
Cash and cash equivalents $ 1,071,876     $ 797,210    
Restricted cash 8,103     8,383    
Short-term investments 46,948     119,146    
Accounts receivable, net 180,340     189,115    
Contract assets 161,357     195,651    
Inventories, net 25,550     32,331    
Prepaid expenses and other current assets 53,022     39,704    
Total current assets 1,547,196     1,381,540    
Long-term investments 52,149     179,587    
Property, plant, and equipment, net 541,963     537,432    
Operating lease right-of-use assets 76,515        
Goodwill and intangible assets, net 489,376     515,720    
Deferred taxes 118,881     114,075    
Other non-current assets 91,245     93,395    
Total assets $ 2,917,325     $ 2,821,749    
     
LIABILITIES AND STOCKHOLDERS’ EQUITY    
Current liabilities:    
Accounts payable $ 12,617     $ 15,212    
Accrued liabilities 219,974     268,144    
Income taxes payable 3,260     3,506    
Contract liabilities 15,436     19,991    
Operating lease liabilities 15,822        
Total current liabilities 267,109     306,853    
Non-current contract liabilities 24,342     24,404    
Non-current operating lease liabilities 65,315        
Other non-current liabilities 122,154     177,462    
Total liabilities 478,920     508,719    
     
Stockholders’ equity:    
Class A common stock 58     58    
Class B common stock 41     41    
Retained earnings 2,443,138     2,327,877    
Accumulated other comprehensive (loss) (10,594 )   (20,625 )  
Total stockholders’ equity – Dolby Laboratories, Inc. 2,432,643     2,307,351    
Controlling interest 5,762     5,679    
Total stockholders’ equity 2,438,405     2,313,030    
Total liabilities and stockholders’ equity $ 2,917,325     $ 2,821,749    







DOLBY LABORATORIES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands; unaudited)

  Fiscal Year-To-Date Ended
  September 25,

2020
September 27,

2019
Operating activities:    
Net income including controlling interest $ 231,619     $ 255,505    
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 90,878     85,123    
Stock-based compensation 86,628     76,580    
Amortization of premium on investments 800     358    
Provision for doubtful accounts 7,689     4,523    
Deferred income taxes (5,274 )   (40,191 )  
Restructuring charge for exit of leased facility 1,640     33,251    
Other non-cash items affecting net income 10,920     6,952    
Changes in operating assets and liabilities:    
Accounts receivable, net 1,251     (27,492 )  
Contract assets 34,297     (29,708 )  
Inventories (11,784 )   (16,098 )  
Operating lease right-of-use assets (13,516 )      
Prepaid expenses and other assets (5,680 )   (6,200 )  
Accounts payable and accrued liabilities (45,185 )   169    
Income taxes, net (50,586 )   (2,186 )  
Contract liabilities (4,621 )   1,084    
Operating lease liabilities 15,618        
Other non-current liabilities (845 )   (13,996 )  
Net cash provided by operating activities 343,849     327,674    
     
Investing activities:    
Purchases of investment securities (287,777 )   (265,361 )  
Proceeds from sales of investment securities 244,517     200,636    
Proceeds from maturities of investment securities 246,621     136,951    
Purchases of property, plant, and equipment (66,347 )   (96,281 )  
Payments for business acquisitions, net of cash acquired     (14,919 )  
Purchase of intangible assets (2,640 )   (17,255 )  
Net cash provided by/(used in) investing activities 134,374     (56,229 )  
     
Financing activities:    
Proceeds from issuance of common stock 82,658     57,346    
Repurchase of common stock (173,742 )   (340,585 )  
Payment of cash dividend (88,581 )   (77,496 )  
Distribution to controlling interest (283 )   (1,015 )  
Shares repurchased for tax withholdings on vesting of restricted stock (23,065 )   (22,788 )  
Payment related to prior purchases of intangible assets (91 )      
Payment of deferred consideration for prior business combination (4,671 )   (743 )  
Net cash used in financing activities (207,775 )   (385,281 )  
     
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash 3,938     (5,821 )  
Net increase/(decrease) in cash, cash equivalents, and restricted cash 274,386     (119,657 )  
Cash, cash equivalents, and restricted cash at beginning of period 805,593     925,250    
Cash, cash equivalents, and restricted cash at end of period $ 1,079,979     $ 805,593    

GAAP to Non-GAAP Reconciliations
(in millions, except per share data; unaudited)
           
The following tables present Dolby’s GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the fourth quarter of fiscal 2020 and 2019 and fiscal 2020 and 2019:
           
Net income: Fiscal Quarter Ended   Fiscal Year Ended
  September 25,

2020
September 27,

2019
  September 25,

2020
September 27,

2019
GAAP net income $ 26.8     $ 43.9       $ 231.4     $ 255.2    
Stock-based compensation (1) 21.8     17.0       86.7     76.6    
Amortization of acquisition-related intangibles (2) 2.5     3.1       10.7     9.9    
Restructuring charges     6.3       1.9     36.5    
Impact of Tax Reform               (18.2 )  
Income tax adjustments (5.3 )   (2.7 )     (25.5 )   (25.4 )  
Non-GAAP net income $ 45.8     $ 67.6       $ 305.2     $ 334.6    
           
(1) Stock-based compensation included in above line items:                
Cost of products and services 0.5     0.4       2.0     1.7    
Research and development 6.3     5.3       25.7     23.2    
Sales and marketing 8.2     5.8       32.0     28.1    
General and administrative 6.8     5.5       27.0     23.6    
                       
(2) Amortization of acquisition-related intangibles included in above line items:                
Cost of licensing 0.7     0.6       3.1      2.4     
Cost of products and services 0.9     1.2       3.6      3.1     
Research and development 0.1     0.1       0.7      0.2     
Sales and marketing 0.8     1.3       3.3      4.2     
General and administrative     (0.1 )     —      —     
           
Diluted earnings per share: Fiscal Quarter Ended   Fiscal Year Ended
  September 25,

2020
September 27,

2019
  September 25,

2020
September 27,

2019
GAAP diluted earnings per share $ 0.26     $ 0.43       $ 2.25     $ 2.44    
Stock-based compensation 0.21     0.17       0.84     0.73    
Amortization of acquisition-related intangibles 0.03     0.03       0.10     0.09    
Restructuring charges     0.06       0.02     0.35    
Impact of Tax Reform               (0.17 )  
Income tax adjustments (0.05 )   (0.03 )     (0.24 )   (0.24 )  
Non-GAAP diluted earnings per share $ 0.45     $ 0.66       $ 2.97     $ 3.20    
           
           
Shares used in computing diluted earnings per share 103     103       103     105    
           
The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial amounts for the first quarter of fiscal 2021 included in this release:
           
Gross margin:         Q1 2021
GAAP gross margin (low – high end of range)         90% – 91%
Stock-based compensation         0.2   %
Amortization of acquisition-related intangibles         0.8   %
Non-GAAP gross margin (low – high end of range)         91% – 92%
           
Operating expenses:         Q1 2021
GAAP operating expenses (low – high end of range)         $207 – $219
Stock-based compensation         (24 )  
Amortization of acquisition-related intangibles         (1 )  
Restructuring charges, net         (7)  – (9)
Non-GAAP operating expenses (low – high end of range)         $175 – $185
           
Diluted earnings per share:     Q1 2021
        Low High
GAAP diluted earnings per share       $ 0.70     $ 0.85    
Stock-based compensation       0.23     0.23    
Amortization of acquisition-related intangibles       0.03     0.03    
Restructuring charges, net       0.08     0.08    
Income tax adjustments       (0.07 )   (0.07 )  
Non-GAAP diluted earnings per share       $ 0.97     $ 1.12    
           
Shares used in computing diluted earnings per share       103     103    



Investor Contact:

Jason Dea
Dolby Laboratories, Inc.
415-357-7002
[email protected]

Media Contact:

Karen Hartquist
Dolby Laboratories, Inc.
415-505-8357
[email protected]

 

IMPORTANT NOV. 16 DEADLINE – Pawar Law Group Announces a Securities Class Action Lawsuit Against Nikola Corporation – NKLA, NKLAW

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nikola Corporation (NASDAQ: NKLA, NKLAW), f/k/a VectoIQ Acquisition Corp. (NASDAQ: VTIQ, VTIQW, VTIQU) from March 3, 2020 through September 20, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Nikola Corporation investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) VectoIQ did not engage in proper due diligence regarding its merger with Nikola; (2) Nikola overstated its “in-house” design, manufacturing, and testing capabilities; (3) Nikola overstated its hydrogen production capabilities; (4) as a result, Nikola overstated its ability to lower the cost of hydrogen fuel; (5) Nikola founder and Executive Chairman, Trevor Milton, tweeted a misleading “test” video of the Company’s Nikola Two truck; (6) the work experience and background of key Nikola employees, including Mr. Milton, had been overstated and obfuscated; (7) Nikola did not have five Tre trucks completed; and (8) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. According to the suit, these true details were disclosed by a market research firm.

If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:  

Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

IIROC Trading Halt – AVCN

Canada NewsWire

TORONTO, Nov. 12, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Avicanna Inc.

TSX Symbol: AVCN

All Issues: Yes

Reason: Pending News

Halt Time (ET): 4:01 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

IIROC Trading Resumption – BRU.H Formerly BRU

Canada NewsWire

VANCOUVER, BC, Nov. 12, 2020 /CNW/ – Trading resumes in:

Company: BRUNSWICK RESOURCES INC.  Formerly BRUNSWICK RESOURCES INC.

TSX-Venture Symbol: BRU.H Formerly BRU

Resumption (ET): 9:30  11/13/2020

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Kodiak Sciences to Present at Upcoming Conferences

PR Newswire

PALO ALTO, Calif., Nov. 12, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming virtual investor conferences:

  • Jefferies Virtual London Healthcare Conference on Tuesday, November 17 at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time)
  • Evercore ISI HealthCONx Conference on Thursday, December 3 at 8:20 a.m. Pacific Time (11:20 a.m. Eastern Time)

A live webcast of both presentations will be available on the “Events and Presentations” section of Kodiak’s website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.

About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak’s discovery engine. Kodiak’s lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Cision View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301172352.html

SOURCE Kodiak Sciences Inc.